Granted Patent B2

US 12,365,878 · App. 17/067,496 · Granted Jul 22, 2025

Inventors: Clodagh O'Shea (San Diego, CA); Michael Lyman (La Jolla, CA); William Partlo (La Jolla, CA); Shigeki Miyake-Stoner (San Diego, CA)

Assignee: Salk Institute for Biological Studies

C12N7/00A61K35/761A61P35/00C07K14/005C12N2710/10321C12N2710/10322C12N2710/10332C12N2710/10371

Abstract

Claims (53)

1. A recombinant adenovirus genome, comprising:

an E1A region encoding a modified E1a protein;

an E3 region encoding an adenovirus death protein (ADP) and comprising a modification or deletion of the coding sequences of each of E3 genes 12.5 k, 6.7 k, 19 k, RIDα, RIDβ and 14.7 k, wherein the modification prevents expression of each of the encoded proteins; and

an E4 region comprising a modification or deletion of the E4orf6/7 coding sequence that prevents expression of the encoded protein, abolishes or impairs its E2F binding site, and/or deletes or impairs the nuclear localization signal.

2. The recombinant adenovirus genome of claim 1 , wherein the modified E1a protein comprises:

a deletion of the LXCXE motif;

a deletion of residues 2-11;

a C124G substitution;

a Y47H substitution;

a Y47H substitution and a C124G substitution; or

a Y47H substitution, a C124G substitution and a deletion of residues 2-11,

wherein the numbering of the preceding modifications is relative to SEQ ID NO: 23.

3. The recombinant adenovirus genome of claim 1 , wherein the modification of the coding sequences of each of E3 genes 12.5 k, 6.7 k, 19 k, RIDα, RIDβ and 14.7 k, comprises a mutation of a start codon, a mutation that introduces a premature stop codon, or both.

4. The recombinant adenovirus genome of claim 1 , further comprising a modification or deletion of E4orf3, wherein the modification prevents expression of the encoded protein.

5. The recombinant adenovirus genome of claim 1 , comprising at least one modification to detarget an adenovirus from the liver.

6. The recombinant adenovirus genome of claim 5 , comprising a mutation in the hexon protein.

7. The recombinant adenovirus genome of claim 6 , wherein the hexon mutation is an E451Q mutation, wherein the numbering is relative to SEQ ID NO: 34.

8. The recombinant adenovirus genome of claim 1 , wherein the genome encodes a chimeric fiber protein.

9. The recombinant adenovirus genome of claim 8 , wherein the chimeric fiber protein comprises a fiber shaft from a first adenovirus serotype and a fiber knob from a second adenovirus serotype.

10. The recombinant adenovirus genome of claim 9 , wherein the first adenovirus serotype of the chimeric fiber protein is Ad5 and the second adenovirus serotype is Ad3, Ad9, Ad11, Ad12, Ad34 or Ad37.

11. The recombinant adenovirus genome of claim 9 , wherein the first adenovirus serotype of the chimeric fiber protein is Ad5 and the second adenovirus serotype is Ad34.

12. The recombinant adenovirus genome of claim 1 , further comprising a heterologous open reading frame (ORF).

13. The recombinant adenovirus genome of claim 12 , wherein the heterologous ORF is operably linked to and in the same reading frame as a self-cleaving peptide coding sequence and the ADP coding sequence, wherein the self-cleaving peptide coding sequence is disposed between the heterologous ORF and the ADP coding sequence.

14. The recombinant adenovirus genome of claim 13 , wherein the self-cleaving peptide is a 2A peptide, or variant thereof.

15. The recombinant adenovirus genome of claim 14 , wherein the 2A peptide comprises a porcine teschovirus-1 (PTV1) 2A (P2A) peptide, a foot and mouth disease virus (FMDV) 2A (F2A) peptide, an equine rhinitis A virus (ERAV) 2A (E2A) peptide or a Thosea asigna virus (TaV) 2A (T2A) peptide, or a variant thereof.

16. The recombinant adenovirus genome of claim 1 , wherein the nucleotide sequence of the genome is at least 95% identical to SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, or SEQ ID NO: 28.

17. A recombinant adenovirus comprising the recombinant adenovirus genome of claim 1 .

18. A composition comprising the recombinant adenovirus of claim 17 and a pharmaceutically acceptable carrier.

19. The recombinant adenovirus genome of claim 1 , wherein:

the modified E1a protein comprises a deletion of the LXCXE motif;

the genome comprises at least one modification in the hexon protein to detarget an adenovirus from the liver;

the genome comprises a heterologous ORF operably linked to and in the same reading frame as a self-cleaving peptide coding sequence and the ADP coding sequence; and

the genome encodes a chimeric fiber protein comprising a fiber shaft from a first adenovirus serotype and a fiber knob from a second adenovirus serotype.

20. The recombinant adenovirus genome of claim 19 , wherein:

the modification or deletion of the coding sequences of each of the E3 genes 12.5 k, 6.7 k, 19 k, RIDα, RIDβ and 14.7 k, comprises deletion of each of the E3 genes 12.5 k, 6.7 k, 19 k, RIDα, RIDβ and 14.7 k;

the hexon modification is E451Q, wherein the numbering is relative to SEQ ID NO: 34;

the self-cleaving peptide is a 2A peptide;

the first adenovirus serotype of the chimeric fiber protein is Ad5 and the second adenovirus serotype is Ad3, Ad9, Ad11, Ad12, Ad34 or Ad37.

21. The recombinant adenovirus genome of claim 20 , wherein the first adenovirus serotype of the chimeric fiber protein is Ad5 and the second adenovirus serotype is Ad34.

22. The recombinant adenovirus genome of claim 20 , wherein the adenovirus is Ad5.

23. The recombinant adenovirus genome of claim 20 , wherein the heterologous ORF is operably linked to and in the same reading frame as the self-cleaving peptide and the ADP coding sequence encodes YPet-P2A-ADP.

24. The recombinant adenovirus genome of claim 23 , wherein the first adenovirus serotype of the chimeric fiber protein is Ad5 and the second adenovirus serotype is Ad34, and wherein the adenovirus is Ad5.

25. The recombinant adenovirus genome of claim 14 , wherein the variant comprises a Gly-Ser-Gly at the N-terminus.

26. The recombinant adenovirus genome of claim 25 , wherein the heterologous ORF encodes a fluorescent protein.

27. The recombinant adenovirus genome of claim 26 , wherein the fluorescent protein is YPet.

28. The recombinant adenovirus genome of claim 1 , wherein the nucleotide sequence of the genome comprises SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, or SEQ ID NO: 59.

29. The recombinant adenovirus genome of claim 1 , wherein the adenovirus genome comprises SEQ ID NO: 13.

30. The recombinant adenovirus genome of claim 1 , wherein the adenovirus genome consists of SEQ ID NO: 13.

31. A recombinant adenovirus comprising the recombinant adenovirus genome of claim 24 .

32. A recombinant adenovirus comprising the recombinant adenovirus genome of claim 29 .

33. A recombinant adenovirus comprising the recombinant adenovirus genome of claim 30 .

34. The recombinant adenovirus genome of claim 1 , wherein the genome encodes a capsid-swapped adenovirus.

35. The recombinant adenovirus genome of claim 24 , wherein the genome encodes a capsid-swapped adenovirus.

Assignments (3)

Continuity (3)

References Cited (400)